ADMA Biologics News - November 4, 2026
ADMA Biologics Surges 27% on a Blowout Quarter — But Can Its Star Drug Carry the Whole Company?
Shares vaulted 27.5% after hours as ADMA Biologics reported third-quarter results that snapped a streak of disappointments, raising an urgent question: whether...
🟢 ADMA Biologics is trading 27.48% up in after-hours trading after Q3 revenue beat
ADMA Biologics is trading at $13.36, up 27.48%, in after-hours trading after Q3 revenue beat expectations. - The price followed the November 4, 2026...
ADMA Biologics third quarter 2026 revenue of $141M beat estimates behind 31% Asceniv growth
ADMA Biologics reported total revenue of $141.1 million for the third quarter 2026, surpassing analyst expectations of $139.8 million. The results were driven...
🔴 ADMA Biologics is trading 5% down; no confirmed catalyst identified
ADMA Biologics is trading at $10.57 (-4.82%), and the reason for the November 4 decline remains unclear. - No confirmed company-specific announcement...